EN DE
Watch AbClon Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

AbClon Inc (174900) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of AbClon Inc stock KRW 11,900, price KRW 20,100, that is 40.8% below the price, quality 35 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7174900001

AI AbClon Inc logo Thin data Nov 10, 2026

AbClon Inc

174900 · KQ
Very expensive, weak quality

Our calculation puts a fair price 41% below what the stock costs today.

Low debt
Revenue last quarter +51% vs. a year ago.
Expensive Growth (revenue 5y +11.2 %/yr in KRW)
Fair value 11,900 KRW · Strongly overvalued
Quality 35/100
Negative free cash flow
Trails peers (2/8)
Narrow moat 8/100
Thin data
Estimate
Watch AbClon Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

89,100 KRW 7,290 KRW Fair Value 11,900 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 7,290 KRW – 89,100 KRW · fair‑value band 8,925 KRW – 14,874 KRW · the 20,100 KRW price screens above the 11,900 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow AbClon in your weekly email

Every Wednesday you see whether AbClon is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden.

Show moreShow less

The company's products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ovarian cancers.

AbClon Inc. was founded in 2010 and is based in Seoul, South Korea.

Stock analysis

AbClon Inc (174900) currently trades at 20,100 KRW, while our estimate is 11,900 KRW, 41% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 8,925 KRW (bear) to 14,874 KRW (bull), the price of 20,100 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

AbClon Inc reported revenue of 4.7B KRW in FY2025 versus 3.0B KRW in FY2021, a compound +11.8%/yr. Reported net income was −17.9B KRW in FY2025.

Key figures

Market cap 384B KRW (≈ $287M) Micro · P/S ratio 70.8 · EPS (TTM) −888.52 KRW · Return on equity −40.8% · Return on assets (EBIT) −26.8% (5-year average) · Operating margin −371% · Revenue (TTM) 5.3B KRW · Revenue growth (YoY) +51.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (medium confidence).

What moves the price

The share trades about 77% below its 52-week high and 23% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at −41%, 174900 screens richer than that median.

Fair Value

Bear 8,925 KRW Fair Value 11,900 KRW Bull 14,874 KRW
Price 20,100 KRW · Downside -40.8%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 35/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 72
Are margins and returns getting better?
Cashflow 6
Do the profits arrive as real cash?
Financial strength 99
Debt, balance sheet and risk of trouble
Investment 34
Does it invest with discipline instead of growing at any price?
Low Volatility 40
How calm the share price moves, does not count
Price momentum 21
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 16
Distance to the 52-week high, does not count
New shares 1
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+101.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.2%
Start year 2020 (pandemic). Over 10 years: +9.2% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−237.1% (2020) → −374.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

174900 screens overvalued: fair value 41% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare AbClon Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 846 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 35 · Below median
Fair Value upside −40.8% · Below median
Profitability
Return on assets −25.3% · Below median
Growth and dividend
Revenue growth (quarter YoY) 51.4% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 6.35× · Priciest 25%
P/S (12 months) 72.30× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $919.96 $1,275 +39% vs 174900
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 174900
Vertex Pharmaceuticals Incorporated VRTX $550.87 $601.80 +9% vs 174900
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 174900
argenx SE ARGX $962.27 $908.40 −6% vs 174900
CSL Limited CSL A$200.73 A$181.40 −10% vs 174900
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 174900
Moderna, Inc MRNA $269.00 $158.70 −41% vs 174900
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 174900
Royalty Pharma plc RPRX $68.77 $19.01 −72% vs 174900

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

AbClon Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "AbClon Inc Fair Value". https://www.fairvalue-calculator.com/stock/174900

Frequently asked questions

Is AbClon Inc (174900) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 11,900 KRW versus a price of 20,100 KRW, about 41% lower (overvalued).
What is the fair value of 174900?
Our estimate for AbClon Inc is 11,900 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 20,100 KRW.
What is the quality score of 174900?
AbClon Inc has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for AbClon Inc (174900)?
Our calculated price target is the estimate of 11,900 KRW (as of Nov 10, 2026). Cautious scenario 8,925 KRW, optimistic scenario 14,874 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the AbClon Inc stock forecast for 2026?
Our estimate puts fair value at 11,900 KRW, about 41% lower versus a price of 20,100 KRW (overvalued). Cautious scenario 8,925 KRW, optimistic scenario 14,874 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of AbClon Inc (174900)?
AbClon Inc reported trailing-twelve-month revenue of about 5.3B KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of AbClon Inc (174900)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For AbClon Inc it is 11,900 KRW per share (as of Nov 10, 2026), against a price of 20,100 KRW.
Is AbClon Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 174900 trades above its calculated fair value: price 20,100 KRW, fair value 11,900 KRW, a gap of about −41% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 174900?
No. The price is what the market pays today (20,100 KRW); the fair value is what the company's own numbers justify (11,900 KRW). For AbClon Inc the two are 8,200 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is AbClon Inc worth?
The market values AbClon Inc at about 384B KRW (market capitalisation, as of Nov 10, 2026). Per share that is 20,100 KRW; our models calculate a fair value of 11,900 KRW per share.
What do the bullish and bearish scenarios say about 174900?
Our models span a range for AbClon Inc: cautious scenario 8,925 KRW, base 11,900 KRW, optimistic 14,874 KRW per share (as of Nov 10, 2026, price 20,100 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of AbClon Inc (174900)?
Balance-sheet figures for AbClon Inc (as of Nov 10, 2026): return on equity −40.8%. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is 174900 from its 52-week high?
AbClon Inc trades at 20,100 KRW, about 77% below its 52-week high of 89,100 KRW and 23% above the low of 16,310 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 11,900 KRW is for.
Which stocks are comparable to AbClon Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is AbClon Inc stock attractive at the current price?
The data as of Nov 10, 2026: price 20,100 KRW, calculated fair value 11,900 KRW (−41%), Quality Score 35/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.2% above its aggregate fair value. AbClon Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of AbClon Inc (174900)?
The closing price on Nov 10, 2026 was 20,100 KRW. Our estimate is 11,900 KRW, about 41% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with AbClon Inc right now?
The price sits above even our optimistic bull case (14,874 KRW). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of AbClon Inc

How large is the market capitalisation of AbClon Inc (174900)?
The market capitalisation of AbClon Inc is 384B KRW (≈ $287M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of AbClon Inc (174900)?
The price-to-sales ratio of AbClon Inc is 70.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of AbClon Inc (174900)?
Earnings per share at AbClon Inc are −888.52 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of AbClon Inc (174900)?
The return on equity (ROE) of AbClon Inc is −40.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of AbClon Inc (174900)?
On an EBIT basis the return on assets of AbClon Inc is −26.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of AbClon Inc (174900)?
The operating margin of AbClon Inc is −371% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at AbClon Inc (174900)?
Revenue at AbClon Inc is growing +51.4% versus a year earlier (3y avg +11.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does AbClon Inc (174900) generate?
The free cash flow of AbClon Inc is −14.4B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does AbClon Inc (174900) carry?
The net debt of AbClon Inc is 269M KRW (fiscal year 2023). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch AbClon Inc in the live analysis

One click puts AbClon Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.